

John R Mascola

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/4930036/publications.pdf](https://exaly.com/author-pdf/4930036/publications.pdf)

Version: 2025-02-01

335

PR articles

57,382

PR citations

455

114

PR h-index

620

234

g-index

376

documents

70595

doc citations

361

130

h-index

53484

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Pre-exposure antibody prophylaxis protects macaques from severe influenza. <i>Science</i> , 2025, 387, 534-541.	37.0	10
2	Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. <i>Science Translational Medicine</i> , 2024, 16, .	13.4	37
3	Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN Tj ETQq1 1 0.784314 rgBT ₉ /Overlo	8.1	
4	A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo. <i>Science Translational Medicine</i> , 2024, 16, .	13.4	2
5	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, .	13.4	125
6	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	34.4	79
7	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. <i>Journal of Infectious Diseases</i> , 2022, 226, 510-520.	3.9	32
8	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 383-391.	40.4	141
9	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	34.4	218
10	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, .	37.0	161
11	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. <i>Advanced Science</i> , 2022, 9, .	12.7	9
12	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101819.	2.3	14
13	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. <i>Nature Medicine</i> , 2022, 28, 1022-1030.	40.4	77
14	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	6.4	420
15	Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1210-1220.	15.7	34
16	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	40.4	117
17	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	2.4	26
18	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022, 48, 101477.	8.5	36

#	ARTICLE	IF	PR CITATIONS
19	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	13.4	12
20	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. <i>PLoS Pathogens</i> , 2022, 18, e1010574.	4.5	14
21	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. <i>Structure</i> , 2022, 30, 1233-1244.e7.	3.9	34
22	Broadly neutralizing antibodies target the coronavirus fusion peptide. <i>Science</i> , 2022, 377, 728-735.	37.0	244
23	Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. <i>Immunity</i> , 2022, 55, 2135-2148.e6.	23.3	23
24	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	37.0	85
25	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 184-192.	4.8	8
26	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , 2021, 9, 73.	3.1	32
27	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	44.0	9,943
28	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021, 64, 103203.	10.0	25
29	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	13.4	71
30	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	44.0	470
31	Quadrivalent influenza nanoparticle vaccines induce broad protection. <i>Nature</i> , 2021, 592, 623-628.	39.5	293
32	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	39.5	2,223
33	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	13.4	421
34	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021, 54, 769-780.e6.	23.3	60
35	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1 Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2021, 224, 1916-1924.	3.9	47
36	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	37.0	199

#	ARTICLE	IF	PR CITATIONS
37	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. PLoS Pathogens, 2021, 17, e1009738.	4.5	12
38	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	34.4	307
39	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	23.3	238
40	Blocking Î± ₄ Î² ₂ integrin delays viral rebound in SHIV	13.4	14
41	A Monoclonal Antibody for Malaria Prevention. New England Journal of Medicine, 2021, 385, 803-814.	44.0	148
42	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, .	13.4	116
43	Durability of mRNA-1273 vaccineâ€“induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	37.0	543
44	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, .	37.0	301
45	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.8	26
46	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization. PLoS Pathogens, 2021, 17, e1009543.	4.5	7
47	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. Journal of Clinical Investigation, 2021, 131, .	9.0	6
48	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 2021, 385, 1774-1785.	44.0	539
49	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Journal of Biological Chemistry, 2021, 297, 101127.	2.3	16
50	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine, 2021, 9, 1111-1120.	24.1	57
51	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€“boosted nonhuman primates. Science, 2021, 374, 1343-1353.	37.0	95
52	A multiclade envâ€“gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021, 27, 2234-2245.	40.4	154
53	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, .	5.1	57
54	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. Journal of Infectious Diseases, 2020, 222, 628-636.	3.9	55

#	ARTICLE	IF	PR CITATIONS
55	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.0	27
56	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. <i>Nature Communications</i> , 2020, 11, .	13.9	53
57	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	39.5	1,481
58	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	6.4	71
59	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18754-18763.	7.8	79
60	An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1920-1931.	44.0	3,090
61	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, .	11.2	74
62	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	44.0	1,058
63	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , 2020, 32, 107981.	6.4	25
64	Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. <i>Vaccines</i> , 2020, 8, 765.	3.1	19
65	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. <i>Frontiers in Immunology</i> , 2020, 11, .	5.1	76
66	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	13.4	44
67	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , 2020, 27, 531-543.e6.	15.5	29
68	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, .	13.9	34
69	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020, 16, e1007626.	3.2	28
70	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. <i>Journal of Immunology</i> , 2020, 204, 1543-1561.	0.6	8
71	Next-generation influenza vaccines: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 239-252.	75.6	304
72	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020, 31, 107488.	6.4	74

#	ARTICLE	IF	PR CITATIONS
73	Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1369.	17.2	99
74	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	37.0	307
75	Delayed vaginal SHIV infection in VRC01 and anti- β 27 treated rhesus macaques. <i>PLoS Pathogens</i> , 2019, 15, e1007776.	4.5	18
76	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019, 178, 567-584.e19.	34.4	150
77	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, .	13.9	40
78	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , 2019, 9, e030283.	2.0	16
79	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. <i>Scientific Reports</i> , 2019, 9, .	3.5	44
80	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019, 26, 336-346.e3.	15.5	123
81	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV</i> , 2019, 6, e667-e679.	8.1	102
82	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	4.5	74
83	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019, 37, 6208-6220.	3.2	27
84	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet</i> , 2019, 393, 889-898.	52.0	120
85	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	23.3	98
86	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. <i>Science Translational Medicine</i> , 2019, 11, .	13.4	64
87	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	2.4	54
88	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	8.1	94
89	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. <i>MBio</i> , 2019, 10, .	4.5	133
90	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	23.3	111

#	ARTICLE	IF	PR CITATIONS
91	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. <i>Nature Immunology</i> , 2019, 20, 362-372.	24.4	302
92	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , 2019, 10, .	13.9	37
93	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. <i>Immunity</i> , 2019, 51, 915-929.e7.	23.3	138
94	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. <i>Nature Communications</i> , 2019, 10, .	13.9	54
95	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , 2019, 27, 196-206.e6.	3.9	88
96	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	15.5	171
97	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	9.0	115
98	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. <i>Pathogens and Immunity</i> , 2019, 4, 294.	1.6	30
99	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018, 92, .	3.7	168
100	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , 2018, 9, .	13.9	75
101	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. <i>ACS Infectious Diseases</i> , 2018, 4, 788-796.	3.7	89
102	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , 2018, 22, 1798-1809.	6.4	71
103	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. <i>Nature Biotechnology</i> , 2018, 36, 152-155.	32.5	137
104	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2116-2127.	3.1	18
105	Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1530-1534.	3.9	7
106	Is It Possible to Develop a "Universal" Influenza Virus Vaccine?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029413.	7.4	45
107	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet, The</i> , 2018, 391, 552-562.	52.0	282
108	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12265-12270.	7.8	102

#	ARTICLE	IF	PR CITATIONS
109	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007431.	4.5	45
110	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	23.3	69
111	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. <i>PLoS Pathogens</i> , 2018, 14, e1007395.	4.5	50
112	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. <i>Immunity</i> , 2018, 48, 855-871.	23.3	329
113	Glycoengineering HIV-1 Env creates "supercharged"™ and "hybrid"™ glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018, 14, e1007024.	4.5	28
114	Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. <i>PLoS Pathogens</i> , 2018, 14, e1007159.	4.5	51
115	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	40.4	306
116	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. <i>PLoS Medicine</i> , 2018, 15, e1002493.	8.1	230
117	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. <i>PLoS Pathogens</i> , 2018, 14, e1006860.	4.5	81
118	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. <i>Journal of Clinical Investigation</i> , 2018, 128, 2089-2103.	9.0	53
119	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. <i>PLoS ONE</i> , 2018, 13, e0193773.	2.4	25
120	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 928-938.	44.0	273
121	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	13.4	159
122	Use of broadly neutralizing antibodies for <sc>HIV</sc>â€1 prevention. <i>Immunological Reviews</i> , 2017, 275, 296-312.	6.6	140
123	The quest for an antibodyâ€based <sc>HIV</sc> vaccine. <i>Immunological Reviews</i> , 2017, 275, 5-10.	6.6	104
124	Antibodyomics: bioinformatics technologies for understanding Bâ€cell immunity to <sc>HIV</sc>â€1. <i>Immunological Reviews</i> , 2017, 275, 108-128.	6.6	37
125	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , 2017, 91, .	3.7	92
126	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	14.4	148

#	ARTICLE	IF	PR CITATIONS
127	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. <i>Immunity</i> , 2017, 46, 804-817.e7.	23.3	117
128	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	6.4	185
129	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. <i>Journal of Biological Chemistry</i> , 2017, 292, 10197-10219.	2.3	33
130	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	3.7	50
131	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	13.4	260
132	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	13.4	90
133	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017, 13, 1115-1122.	12.2	126
134	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017, 358, 85-90.	37.0	254
135	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	13.4	123
136	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	13.4	94
137	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8614-8619.	7.8	47
138	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	3.7	45
139	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.7	66
140	Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. <i>Frontiers in Immunology</i> , 2017, 8, .	5.1	95
141	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017, 13, e1006148.	4.5	61
142	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	8.1	120
143	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, .	13.9	84
144	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.4	33

#	ARTICLE	IF	PR CITATIONS
145	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS ONE, 2017, 12, e0186854.	2.4	52
146	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.5	41
147	SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. Frontiers in Immunology, 2016, 7, .	5.1	78
148	Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Computational Biology, 2016, 12, e1004940.	3.2	37
149	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.5	182
150	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathogens, 2016, 12, e1005537.	4.5	67
151	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity, 2016, 44, 939-950.	23.3	94
152	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	34.4	433
153	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.7	73
154	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science, 2016, 352, 828-833.	37.0	370
155	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	3.8	48
156	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 2016, 166, 1471-1484.e18.	34.4	240
157	Rapid development of a DNA vaccine for Zika virus. Science, 2016, 354, 237-240.	37.0	384
158	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. Journal of Virology, 2016, 90, 10574-10586.	3.7	40
159	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure, 2016, 24, 1346-1357.	3.9	40
160	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nature Structural and Molecular Biology, 2016, 23, 811-820.	8.7	157
161	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	34.4	340
162	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	23.3	385

#	ARTICLE	IF	PR CITATIONS
163	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2016, 375, 2037-2050.	44.0	459
164	An HIV-1 Env Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. <i>Journal of Immunology</i> , 2016, 197, 3982-3998.	0.6	21
165	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. <i>Nature Medicine</i> , 2016, 22, 1456-1464.	40.4	309
166	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. <i>Nature Medicine</i> , 2016, 22, 362-368.	40.4	185
167	High-Resolution Longitudinal Study of HIV-1 Env Vaccine Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. <i>Journal of Immunology</i> , 2016, 196, 3729-3743.	0.6	30
168	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016, 351, 1339-1342.	37.0	411
169	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	34.4	344
170	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , 2016, 90, 2740-2755.	3.7	60
171	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , 2016, 90, 1321-1332.	3.7	81
172	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	3.7	238
173	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016, 11, e0157409.	2.4	57
174	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2015, 10, e0128779.	2.4	46
175	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. <i>Journal of Virology</i> , 2015, 89, 5318-5329.	3.7	144
176	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	34.4	347
177	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, .	13.4	441
178	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. <i>Lancet, The</i> , 2015, 385, 1545-1554.	52.0	119
179	HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies. <i>Journal of Virology</i> , 2015, 89, 4201-4213.	3.7	146
180	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. <i>Journal of Virology</i> , 2015, 89, 2659-2671.	3.7	133

#	ARTICLE	IF	PR CITATIONS
181	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathogens, 2015, 11, e1004932.	4.5	146
182	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, .	13.9	282
183	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015, 349, .	37.0	206
184	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. Science Translational Medicine, 2015, 7, .	13.4	129
185	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nature Structural and Molecular Biology, 2015, 22, 522-531.	8.7	375
186	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature Communications, 2015, 6, .	13.9	93
187	Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization. Journal of Immunology, 2015, 194, 5903-5914.	0.6	24
188	Antibody responses to envelope glycoproteins in HIV-1 infection. Nature Immunology, 2015, 16, 571-576.	24.4	385
189	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell, 2015, 161, 470-485.	34.4	251
190	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. Journal of Virology, 2015, 89, 5895-5903.	3.7	103
191	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine, 2015, 33, 7344-7351.	3.2	19
192	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell, 2015, 162, 1090-1100.	34.4	364
193	Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications, 2015, 6, .	13.9	95
194	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2015, 89, 8334-8345.	3.7	114
195	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. MBio, 2015, 6, .	4.5	31
196	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	15.5	72
197	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nature Structural and Molecular Biology, 2015, 23, 81-90.	8.7	185
198	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Science Translational Medicine, 2014, 6, .	13.4	240

#	ARTICLE	IF	PR CITATIONS
199	HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization. PLoS Pathogens, 2014, 10, e1004337.	4.5	25
200	Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6. Journal of Virology, 2014, 88, 2426-2441.	3.7	44
201	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. Journal of Immunological Methods, 2014, 409, 131-146.	1.5	540
202	Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline. Journal of Immunology, 2014, 192, 1100-1106.	0.6	94
203	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014, 509, 55-62.	39.5	737
204	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 2014, 211, 2061-2074.	8.0	330
205	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i>. Journal of Virology, 2014, 88, 12669-12682.	3.7	287
206	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2014, 88, 2489-2507.	3.7	337
207	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. Cell Host and Microbe, 2014, 16, 304-313.	15.5	151
208	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	34.4	291
209	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. Journal of Virology, 2014, 88, 12623-12643.	3.7	80
210	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, The, 2014, 384, 2046-2052.	52.0	229
211	Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization. Journal of Immunology, 2014, 192, 3637-3644.	0.6	60
212	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	39.5	775
213	Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies. Journal of Virology, 2014, 88, 14002-14016.	3.7	49
214	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine, 2014, 20, 1126-1129.	40.4	333
215	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids, 2014, 28, 163-169.	2.5	372
216	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. Journal of Clinical Investigation, 2014, 124, 1835-1843.	9.0	98

#	ARTICLE	IF	PR CITATIONS
217	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	23.3	390
218	Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5Å... Cocystal Structure of gp120 and M48U1. <i>Structure</i> , 2013, 21, 1018-1029.	3.9	29
219	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	44.0	566
220	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. <i>Journal of Virology</i> , 2013, 87, 2294-2306.	3.7	34
221	<scp>HIV</scp> neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013, 254, 225-244.	6.6	476
222	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	39.5	1,043
223	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	23.3	392
224	Mining the antibodyome for HIV-1 neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6470-6475.	7.8	149
225	Structural basis for diverse N-glycan recognition by HIV-1 neutralizing V1 directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 804-813.	8.7	272
226	De novo identification of VRC01 class HIV-1 neutralizing antibodies by next-generation sequencing of B-cell transcripts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, .	7.8	108
227	Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains. <i>Journal of Virology</i> , 2013, 87, 10047-10058.	3.7	68
228	Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates. <i>Journal of Virology</i> , 2013, 87, 13239-13251.	3.7	65
229	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDS VAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	2.4	175
230	N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementations of Function. <i>PLoS ONE</i> , 2013, 8, e55701.	2.4	38
231	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e59340.	2.4	80
232	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	2.4	227
233	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2013, 505, 502-508.	39.5	147
234	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. <i>Journal of Virology</i> , 2012, 86, 4394-4403.	3.7	115

#	ARTICLE	IF	PR CITATIONS
235	BLYS-Mediated Modulation of Naive B Cell Subsets Impacts HIV Env-Induced Antibody Responses. <i>Journal of Immunology</i> , 2012, 188, 6018-6026.	0.6	34
236	Most rhesus macaques infected with the CCR5-tropic SHIV _{AD8} generate cross-reactive antibodies that neutralize multiple HIV-1 strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19769-19774.	7.8	75
237	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. <i>Journal of Virology</i> , 2012, 86, 3393-3397.	3.7	77
238	Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site. <i>Journal of Biological Chemistry</i> , 2012, 287, 5673-5686.	2.3	50
239	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	1.5	202
240	Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. <i>Journal of Immunology</i> , 2012, 189, 4816-4824.	0.6	60
241	Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. <i>Immunity</i> , 2012, 37, 412-425.	23.3	446
242	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. <i>Journal of Virology</i> , 2012, 86, 7760-7770.	3.7	35
243	HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. <i>Journal of Virology</i> , 2012, 86, 11231-11241.	3.7	62
244	Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site. <i>Journal of Virology</i> , 2012, 86, 5844-5856.	3.7	82
245	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} in Rhesus Macaques: Implications for Use in Vaccine Studies. <i>Journal of Virology</i> , 2012, 86, 8516-8526.	3.7	49
246	Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4 ⁺ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding. <i>Journal of Virology</i> , 2012, 86, 8672-8680.	3.7	101
247	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , 2012, 491, 406-412.	39.5	824
248	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	3.7	137
249	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. <i>Journal of Virology</i> , 2012, 86, 4688-4692.	3.7	169
250	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5663-5668.	7.8	234
251	High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site. <i>Science Translational Medicine</i> , 2012, 4, .	13.4	114
252	Somatic populations of PGT135 ¹³⁷ HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatic. <i>Frontiers in Microbiology</i> , 2012, 3, .	3.9	71

#	ARTICLE	IF	PR CITATIONS
253	Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4382-4396.	6.7	92
254	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 1396-1404.	3.9	156
255	Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. <i>Journal of Virology</i> , 2011, 85, 8954-8967.	3.7	228
256	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	3.7	413
257	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 11502-11519.	3.7	175
258	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. <i>Science</i> , 2011, 333, 1593-1602.	37.0	823
259	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 916-924.	15.7	187
260	Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2011, 85, 2524-2535.	3.7	49
261	HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 877-887.	1.5	62
262	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. <i>Journal of Virology</i> , 2011, 85, 11401-11408.	3.7	82
263	Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2011, 85, 6906-6912.	3.7	68
264	Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a007278-a007278.	6.7	139
265	The <i>TRIM5</i> Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2011, 85, 10389-10398.	3.7	44
266	Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses. <i>Journal of Virology</i> , 2011, 85, 5465-5475.	3.7	47
267	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	39.5	837
268	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. <i>Science Translational Medicine</i> , 2011, 3, .	13.4	178
269	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. <i>PLoS ONE</i> , 2010, 5, e9015.	2.4	126
270	Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. <i>Journal of Experimental Medicine</i> , 2010, 207, 2003-2017.	8.0	107

#	ARTICLE	IF	PR CITATIONS
271	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. <i>Journal of Virology</i> , 2010, 84, 1631-1636.	3.7	318
272	Influence of Novel CD4 Binding-Defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T-Cell Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2010, 84, 1683-1695.	3.7	44
273	Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region. <i>Journal of Virology</i> , 2010, 84, 2955-2962.	3.7	109
274	The Role of Antibodies in HIV Vaccines. <i>Annual Review of Immunology</i> , 2010, 28, 413-444.	30.4	365
275	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. <i>Science</i> , 2010, 329, 811-817.	37.0	1,130
276	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	37.0	1,718
277	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. <i>Journal of Virology</i> , 2010, 84, 1439-1452.	3.7	632
278	Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. <i>Journal of Virology</i> , 2009, 83, 540-551.	3.7	54
279	Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. <i>Journal of Virology</i> , 2009, 83, 10892-10907.	3.7	87
280	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site. <i>PLoS Pathogens</i> , 2009, 5, e1000445.	4.5	114
281	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. <i>Journal of Virology</i> , 2009, 83, 5077-5086.	3.7	45
282	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009, 206, 1117-1134.	8.0	299
283	A method for identification of HIV gp140 binding memory B cells in human blood. <i>Journal of Immunological Methods</i> , 2009, 343, 65-67.	1.5	217
284	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. <i>Nature Medicine</i> , 2009, 15, 866-870.	40.4	394
285	Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120. <i>Science</i> , 2009, 326, 1123-1127.	37.0	276
286	Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 347-351.	3.3	49
287	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. <i>Vaccine</i> , 2008, 26, 6338-6343.	3.2	242
288	B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4. <i>PLoS Pathogens</i> , 2008, 4, e1000171.	4.5	58

#	ARTICLE	IF	PR CITATIONS
289	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. <i>Journal of Infectious Diseases</i> , 2007, 196, 1732-1740.	3.9	183
290	Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. <i>Journal of Virology</i> , 2007, 81, 5579-5593.	3.7	101
291	Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection. <i>Journal of Virology</i> , 2007, 81, 13486-13498.	3.7	50
292	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. <i>Vaccine</i> , 2007, 25, 4085-4092.	3.2	137
293	Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions. <i>PLoS Medicine</i> , 2007, 4, e348.	8.1	80
294	Broad HIV-1 neutralization mediated by CD4-binding site antibodies. <i>Nature Medicine</i> , 2007, 13, 1032-1034.	40.4	369
295	Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. <i>Virology</i> , 2006, 350, 34-47.	2.3	102
296	Gene transfer in humans using a conditionally replicating lentiviral vector. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17372-17377.	7.8	470
297	Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys. <i>Science</i> , 2006, 312, 1530-1533.	37.0	348
298	Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge. <i>Journal of Virology</i> , 2006, 80, 10950-10956.	3.7	54
299	Preservation of Functional Virus-Specific Memory CD8+ T Lymphocytes in Vaccinated, Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Immunology</i> , 2006, 176, 5338-5345.	0.6	34
300	Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. <i>Journal of Virology</i> , 2005, 79, 2956-2963.	3.7	120
301	A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates. <i>Journal of Virology</i> , 2005, 79, 8828-8834.	3.7	171
302	Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus-Induced IL-2 Expression by Central Memory CD4+ T Lymphocytes. <i>Journal of Immunology</i> , 2005, 174, 4753-4760.	0.6	28
303	Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys. <i>Journal of Virology</i> , 2005, 79, 4580-4588.	3.7	27
304	Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 2023-2033.	8.0	186
305	Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins. <i>Journal of Virology</i> , 2005, 79, 771-779.	3.7	101
306	Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2005, 79, 6516-6522.	3.7	142

#	ARTICLE	IF	PR CITATIONS
307	Differential Susceptibility to Human Immunodeficiency Virus Type 1 Infection of Myeloid and Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2005, 79, 8861-8869.	3.7	198
308	Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. <i>Journal of Virology</i> , 2005, 79, 10902-10914.	3.7	35
309	Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. <i>Journal of Virology</i> , 2005, 79, 10108-10125.	3.7	1,076
310	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. <i>Journal of Virology</i> , 2004, 78, 5520-5522.	3.7	23
311	Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins. <i>Journal of Virology</i> , 2004, 78, 5270-5278.	3.7	40
312	Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope. <i>Journal of Virology</i> , 2004, 78, 10724-10737.	3.7	472
313	Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys. <i>Journal of Virology</i> , 2004, 78, 7490-7497.	3.7	127
314	Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope. <i>Journal of Virology</i> , 2004, 78, 4029-4036.	3.7	69
315	Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 807-816.	1.5	27
316	Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies. <i>Journal of Virology</i> , 2003, 77, 10348-10356.	3.7	50
317	Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. <i>Aids</i> , 2003, 17, 2521-2527.	2.5	64
318	Defining the Protective Antibody Response for HIV-1. <i>Current Molecular Medicine</i> , 2003, 3, 209-216.	2.2	122
319	Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. <i>Journal of Virology</i> , 2002, 76, 4810-4821.	3.7	108
320	Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination. <i>Journal of Virology</i> , 2002, 76, 11484-11490.	3.7	47
321	Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1021-1034.	1.5	27
322	Vaccines for the prevention of HIV-1 disease. <i>Current Opinion in Immunology</i> , 2001, 13, 489-494.	5.3	62
323	Human Dendritic Cells as Targets of Dengue Virus Infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 219-224.	2.1	155
324	Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. <i>Aids</i> , 2000, 14, 1009-1015.	2.5	103

#	ARTICLE	IF	PR CITATIONS
325	Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. <i>Nature Medicine</i> , 2000, 6, 207-210.	40.4	1,258
326	Human skin Langerhans cells are targets of dengue virus infection. <i>Nature Medicine</i> , 2000, 6, 816-820.	40.4	626
327	Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion. <i>Journal of Virology</i> , 2000, 74, 11329-11338.	3.7	109
328	Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2557-2563.	4.1	124
329	Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. <i>Journal of Virology</i> , 1999, 73, 4009-4018.	3.7	743
330	A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-React with Other HIV Type 1 Clades. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 213-221.	1.5	24
331	The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. <i>Nature Medicine</i> , 1997, 3, 338-340.	40.4	483
332	Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1319-1328.	1.5	79
333	Induction of HIV Type 1 Neutralizing and <i>env</i> -CD4 Blocking Antibodies by Immunization with Genetically Engineered HIV Type 1-Like Particles Containing Unprocessed gp160 Glycoproteins. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1187-1195.	1.5	21
334	Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization Serotype. <i>Journal of Infectious Diseases</i> , 1994, 169, 48-54.	3.9	195
335	Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine Trials. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 1175-1184.	1.5	99